Activity Details

Accredited By

This continuing medical education activity is provided by the Cleveland Clinic Foundation Center for Continuing Education.



Educational Partner:

Target Audience

The intended audience for this activity is allergists, dermatologists, and other health care professionals (nurses and physician assistants) involved in the management of patients with moderate to severe atopic dermatitis.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

• Examine the latest clinical safety and efficacy data for available and emerging JAK inhibitors in the management of patients with moderate to severe atopic dermatitis.
• Assess new evidence regarding the use of JAK inhibitors as monotherapy or combination therapy for the treatment of moderate to severe atopic dermatitis, in general, and compared to other therapies with different mechanisms of action.

Activity Description

Atopic dermatitis (AD) affects up to 30% of children and 5% of adults. Although 70% of patients have mild disease, which can be treated with basic skincare management and topical agents, 30% have moderate to severe AD, which is substantially more difficult to treat. Until recently, systemic steroids were the only treatment option for these patients, but they have limited efficacy with a poor safety profile. The recent advent and availability of non-steroidal systemic treatment options revolutionized the management of moderate to severe AD, not only providing significant improvement in clinical outcomes, but also heralding a new era in drug development for AD. In addition to biologics, oral therapies that target a variety of signaling molecules (eg, PDE4, Janus Kinase [JAK], prostaglandin receptors) are also emerging. As data continue to emerge on new agents, head-to-head comparative study results on JAK inhibitors are becoming available, further elucidating their role in the treatment algorithm for moderate to severe AD. In this educational activity, expert faculty in the field of AD explore the most recent clinical data for available and emerging JAK inhibitors and assess new evidence regarding the use of these agents as monotherapy and combination therapy, as compared to other therapies with different mechanisms of action.

Agenda

Program Introduction and Overview of JAK Inhibitors for Moderate to Severe Atopic Dermatitis
Anthony P. Fernandez, MD, PhD

The Efficacy of JAK Inhibitors as Systemic Therapy for AD
Amy S. Paller, MS, MD

The Safety of Systemic JAK Inhibitors for AD
Andrew Blauvelt, MD, MBA

Activity Chair

Anthony P. Fernandez, MD, PhD
Assistant Professor of Clinical Medicine, CCLCM
Co-Medical Director of Continuing Medical Education
Director of Medical Dermatology
W.D. Steck Chair of Clinical Dermatology
Staff Physician, Departments of Dermatology and Pathology
Cleveland Clinic
Cleveland, Ohio

Faculty

Andrew Blauvelt, MD, MBA
President
Oregon Medical Research Center
Portland, OR

Amy S. Paller, MS, MD
Walter J. Hamlin Professor and Chair, Department of Dermatology
Professor, Department of Pediatrics
The Feinberg School of Medicine of Northwestern University
Chicago, IL

Reviewers

Deb Kangisser, PA-C
Cleveland Clinic
Cleveland, OH

Cindy Willis, DNP
Cleveland Clinic
Cleveland, OH

Sarah Young, MD
Department of Dermatology
Dermatology and Plastic Surgery Institute
Cleveland Clinic
Cleveland, OH

Conflict of Interest Policy/Disclosure Statement

Cleveland Clinic Foundation Center for Continuing Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Andrew Blauvelt, MD, MBA
Consulting: Almirall, Amgen, Arena Pharmaceuticals, Boehringer Ingelheim, Bristol-Myers Squibb Co., Celgene Corporation, Dermavant Sciences, Inc., Eli Lilly, Galderma Labs LP, Incyte, Janssen Pharmaceuticals, Inc., LEO Pharma, Novartis, Regeneron, Sanofi, Sun Pharmaceutical Industries Ltd.
Consulting and Teaching and Speaking: AbbVie Pharmaceuticals, Pfizer, UCB

Anthony Fernandez, MD, PhD
Consulting: Bristol-Myers Squibb Co., UCB, Inc.
Consulting and Teaching and Speaking: Mallinckrodt Inc., Novartis
Consulting, Advisor or review panel participant, and Teaching and Speaking: AbbVie Pharmaceuticals
Awarded a grant to fund a medical dermatology fellowship position: Pfizer, Inc.
Teaching and Speaking: Kyowa Kirin

Amy S. Paller, MS, MD
Consulting, Data Safety Monitoring Board, Principal Investigator: AbbVie Pharmaceuticals
Consulting: Acrotech, Almirall, S.A., Arcutis, BiomX, Boehringer Ingelheim GmbH, Botanix, Bristol-Myers Squibb Co., Catawba, Genzyme/Sanofi, Gilead Sciences, Inc., LEO Pharma, Novartis Pharmaceuticals, Pfizer, Inc., RAPT Therapeutics, Seanergy, Union Therapeutics
Consulting, Principal Investigator: Eli Lilly, Regeneron
Data Safety Monitoring Board: Bausch Health, Galderma
Principal Investigator: Dermavant Sciences, Inc., Incyte, Janssen Research & Development, LLC

Reviewers report no relevant financial relationships to disclose.

Cleveland Clinic Foundation Center for Continuing Education and Vindico Medical Education staff report no relevant financial relationships to disclose.

Signed disclosures are on file at Cleveland Clinic Foundation Center for Continuing Education and Vindico Medical Education, Office of Medical Affairs and Compliance.

Accreditation

In support of improving patient care, Cleveland Clinic Center for Continuing Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

Cleveland Clinic Foundation Center for Continuing Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association for Category 2 credit.

Cleveland Clinic Center for Continuing Education designates this enduring activity for a maximum of 1.25 ANCC contact hours.

Cleveland Clinic Center for Continuing Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.25 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

This activity offers 2 ABD MOC self-assessment credits approved by the American Board of Dermatology (ABD). Successful completion of the online self-assessment enables the participant to earn 2 ABD MOC self-assessment credits, in addition to any AMA PRA Category 1 Credit™ claimed for the enduring activity.

How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objective, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 5 of the 6 posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Cleveland Clinic Foundation Center for Continuing Education will issue a certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Pfizer, Inc.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2022 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Cleveland Clinic Foundation Center for Continuing Education and Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Cleveland Clinic Foundation Center for Continuing Education or Vindico Medical Education. Neither Cleveland Clinic Foundation Center for Continuing Education, Vindico Medical Education, nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at cme@vindicoCME.com and/or mycme@ccf.org.

Activity Details

Accredited By

This continuing medical education activity is provided by the Cleveland Clinic Foundation Center for Continuing Education.



Educational Partner:

Target Audience

The intended audience for this activity is allergists, dermatologists, and other health care professionals (nurses and physician assistants) involved in the management of patients with moderate to severe atopic dermatitis.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

• Examine the latest clinical safety and efficacy data for available and emerging JAK inhibitors in the management of patients with moderate to severe atopic dermatitis.
• Assess new evidence regarding the use of JAK inhibitors as monotherapy or combination therapy for the treatment of moderate to severe atopic dermatitis, in general, and compared to other therapies with different mechanisms of action.

Activity Description

Atopic dermatitis (AD) affects up to 30% of children and 5% of adults. Although 70% of patients have mild disease, which can be treated with basic skincare management and topical agents, 30% have moderate to severe AD, which is substantially more difficult to treat. Until recently, systemic steroids were the only treatment option for these patients, but they have limited efficacy with a poor safety profile. The recent advent and availability of non-steroidal systemic treatment options revolutionized the management of moderate to severe AD, not only providing significant improvement in clinical outcomes, but also heralding a new era in drug development for AD. In addition to biologics, oral therapies that target a variety of signaling molecules (eg, PDE4, Janus Kinase [JAK], prostaglandin receptors) are also emerging. As data continue to emerge on new agents, head-to-head comparative study results on JAK inhibitors are becoming available, further elucidating their role in the treatment algorithm for moderate to severe AD. In this educational activity, expert faculty in the field of AD explore the most recent clinical data for available and emerging JAK inhibitors and assess new evidence regarding the use of these agents as monotherapy and combination therapy, as compared to other therapies with different mechanisms of action.

Agenda

Program Introduction and Overview of JAK Inhibitors for Moderate to Severe Atopic Dermatitis
Anthony P. Fernandez, MD, PhD

The Efficacy of JAK Inhibitors as Systemic Therapy for AD
Amy S. Paller, MS, MD

The Safety of Systemic JAK Inhibitors for AD
Andrew Blauvelt, MD, MBA

Activity Chair

Anthony P. Fernandez, MD, PhD
Assistant Professor of Clinical Medicine, CCLCM
Co-Medical Director of Continuing Medical Education
Director of Medical Dermatology
W.D. Steck Chair of Clinical Dermatology
Staff Physician, Departments of Dermatology and Pathology
Cleveland Clinic
Cleveland, Ohio

Faculty

Andrew Blauvelt, MD, MBA
President
Oregon Medical Research Center
Portland, OR

Amy S. Paller, MS, MD
Walter J. Hamlin Professor and Chair, Department of Dermatology
Professor, Department of Pediatrics
The Feinberg School of Medicine of Northwestern University
Chicago, IL

Reviewers

Deb Kangisser, PA-C
Cleveland Clinic
Cleveland, OH

Cindy Willis, DNP
Cleveland Clinic
Cleveland, OH

Sarah Young, MD
Department of Dermatology
Dermatology and Plastic Surgery Institute
Cleveland Clinic
Cleveland, OH

Conflict of Interest Policy/Disclosure Statement

Cleveland Clinic Foundation Center for Continuing Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Andrew Blauvelt, MD, MBA
Consulting: Almirall, Amgen, Arena Pharmaceuticals, Boehringer Ingelheim, Bristol-Myers Squibb Co., Celgene Corporation, Dermavant Sciences, Inc., Eli Lilly, Galderma Labs LP, Incyte, Janssen Pharmaceuticals, Inc., LEO Pharma, Novartis, Regeneron, Sanofi, Sun Pharmaceutical Industries Ltd.
Consulting and Teaching and Speaking: AbbVie Pharmaceuticals, Pfizer, UCB

Anthony Fernandez, MD, PhD
Consulting: Bristol-Myers Squibb Co., UCB, Inc.
Consulting and Teaching and Speaking: Mallinckrodt Inc., Novartis
Consulting, Advisor or review panel participant, and Teaching and Speaking: AbbVie Pharmaceuticals
Awarded a grant to fund a medical dermatology fellowship position: Pfizer, Inc.
Teaching and Speaking: Kyowa Kirin

Amy S. Paller, MS, MD
Consulting, Data Safety Monitoring Board, Principal Investigator: AbbVie Pharmaceuticals
Consulting: Acrotech, Almirall, S.A., Arcutis, BiomX, Boehringer Ingelheim GmbH, Botanix, Bristol-Myers Squibb Co., Catawba, Genzyme/Sanofi, Gilead Sciences, Inc., LEO Pharma, Novartis Pharmaceuticals, Pfizer, Inc., RAPT Therapeutics, Seanergy, Union Therapeutics
Consulting, Principal Investigator: Eli Lilly, Regeneron
Data Safety Monitoring Board: Bausch Health, Galderma
Principal Investigator: Dermavant Sciences, Inc., Incyte, Janssen Research & Development, LLC

Reviewers report no relevant financial relationships to disclose.

Cleveland Clinic Foundation Center for Continuing Education and Vindico Medical Education staff report no relevant financial relationships to disclose.

Signed disclosures are on file at Cleveland Clinic Foundation Center for Continuing Education and Vindico Medical Education, Office of Medical Affairs and Compliance.

Accreditation

In support of improving patient care, Cleveland Clinic Center for Continuing Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

Cleveland Clinic Foundation Center for Continuing Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association for Category 2 credit.

Cleveland Clinic Center for Continuing Education designates this enduring activity for a maximum of 1.25 ANCC contact hours.

Cleveland Clinic Center for Continuing Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.25 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

This activity offers 2 ABD MOC self-assessment credits approved by the American Board of Dermatology (ABD). Successful completion of the online self-assessment enables the participant to earn 2 ABD MOC self-assessment credits, in addition to any AMA PRA Category 1 Credit™ claimed for the enduring activity.

How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objective, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 5 of the 6 posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Cleveland Clinic Foundation Center for Continuing Education will issue a certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Pfizer, Inc.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2022 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Cleveland Clinic Foundation Center for Continuing Education and Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Cleveland Clinic Foundation Center for Continuing Education or Vindico Medical Education. Neither Cleveland Clinic Foundation Center for Continuing Education, Vindico Medical Education, nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at cme@vindicoCME.com and/or mycme@ccf.org.

Activity Details

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for dermatologist and allergy/immunologist clinicians (MD/DO/NP/PA) who treat patients with chronic spontaneous urticaria (CSU).

Learning Objectives

Upon completion of this activity, participants should be better able to:

• Employ current management approaches for patients with chronic spontaneous urticaria (CSU)
• Identify elements of type 2 inflammation that play a role in CSU pathogenesis that may be amenable to treatment
• Assess current safety and efficacy data on emerging therapies for the treatment of CSU

Activity Description

Treatment options for chronic spontaneous urticaria (CSU) are limited, with up to 40% of patients not responding to first-line therapy and a third not responding to second-line treatment. Moreover, many will continue to remain refractory in the third-line setting, highlighting the need for newer therapeutic agents. This Clinical Transfers^® activity brings to you the latest data on emerging therapies from this year’s annual meeting of allergists and immunologists in Phoenix, AZ.

Faculty

Jonathan A. Bernstein, MD
Professor, Medicine
University of Cincinnati College of Medicine
Department of Internal Medicine
Division of Immunology/Allergy Section and
Bernstein Allergy Group
Bernstein Clinical Research Center
Cincinnati, OH

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.

Faculty

Jonathan A. Bernstein, MD, has relevant financial relationships with AstraZeneca, BioCryst, BioMarin, Blueprint Medicine, Celldex, CSL Behring, Ionis, Genentech, Novartis, Pharming, Pharvaris, Sanofi Regeneron, Takeda/Shire (Consultant and Researcher); AstraZeneca, BioCryst, CSL Behring, Genentech, GSK, Novartis, Pharming, Sanofi Regeneron, Takeda/Shire (Speaker/Speaker’s Bureau).

All of the relevant financial relationships listed for this individual has been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

• Read the learning objectives and faculty disclosures
• Participate in the activity
• Complete the activity evaluation and attest to credit

In order to claim MOC points, users must:

• Provide ABIM ID and month/date of birth and score 75% or higher on the post-test

MOC points will be submitted to ABIM profiles within 4 weeks of completion.

There is no fee to participate.

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

Supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Activity Details

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for dermatologist and allergy/immunologist clinicians (MD/DO/NP/PA) who treat patients with chronic spontaneous urticaria (CSU).

Learning Objectives

Upon completion of this activity, participants should be better able to:

• Employ current management approaches for patients with chronic spontaneous urticaria (CSU)
• Identify elements of type 2 inflammation that play a role in CSU pathogenesis that may be amenable to treatment
• Assess current safety and efficacy data on emerging therapies for the treatment of CSU

Activity Description

Treatment options for chronic spontaneous urticaria (CSU) are limited, with up to 40% of patients not responding to first-line therapy and a third not responding to second-line treatment. Moreover, many will continue to remain refractory in the third-line setting, highlighting the need for newer therapeutic agents. This Clinical Transfers^® activity brings to you the latest data on emerging therapies from this year’s annual meeting of allergists and immunologists in Phoenix, AZ.

Faculty

Jonathan A. Bernstein, MD
Professor, Medicine
University of Cincinnati College of Medicine
Department of Internal Medicine
Division of Immunology/Allergy Section and
Bernstein Allergy Group
Bernstein Clinical Research Center
Cincinnati, OH

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.

Faculty

Jonathan A. Bernstein, MD, has relevant financial relationships with AstraZeneca, BioCryst, BioMarin, Blueprint Medicine, Celldex, CSL Behring, Ionis, Genentech, Novartis, Pharming, Pharvaris, Sanofi Regeneron, Takeda/Shire (Consultant and Researcher); AstraZeneca, BioCryst, CSL Behring, Genentech, GSK, Novartis, Pharming, Sanofi Regeneron, Takeda/Shire (Speaker/Speaker’s Bureau).

All of the relevant financial relationships listed for this individual has been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

• Read the learning objectives and faculty disclosures
• Participate in the activity
• Complete the activity evaluation and attest to credit

In order to claim MOC points, users must:

• Provide ABIM ID and month/date of birth and score 75% or higher on the post-test

MOC points will be submitted to ABIM profiles within 4 weeks of completion.

There is no fee to participate.

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

Supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Activity Details

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for dermatology and medical oncology clinicians (MD/DO/NP/PA) involved in the care of patients with nonmelanoma skin cancers (NMSC).

Learning Objectives

Upon completion of this activity, participants should be better able to:

• Select appropriate immunotherapy for patients with advanced nonmelanoma skin cancer (NMSC) based on current safety and efficacy data
• Integrate the unique roles and responsibilities of the interprofessional care team when managing patients with advanced NMSC

Activity Description

This activity features an interprofessional, multidisciplinary panel of experts offering privileged insights on evidence-based immunotherapy selection and collaborative care in advanced cutaneous squamous cell carcinoma (CSCC) and basal cell carcinoma (BCC).

Chair

Vishal Anil Patel, MD, FAAD, FACMS
Director, Cutaneous Oncology, GW Cancer Center
Director, Dermatologic Surgery, GW Department of Dermatology
Assistant Professor, Dermatology & Hematology/Oncology
Washington, DC

Faculty

David M. Miller, MD, PhD, FAAD
Medical Oncologist, Dermatologist
Massachusetts General Hospital
Director, Center for Merkel Cell Carcinoma
Co-Director, NMSC Multi-Disciplinary Clinic
Department of Medicine, Division of Hematology/Oncology
Department of Dermatology
Massachusetts General Cancer Center
Boston, MA

Krista M. Rubin, MS, RN, FNP-BC
Nurse Practitioner, Center for Melanoma
Massachusetts General Hospital
Boston, MA

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.

Faculty

Vishal Anil Patel, MD, FAAD, FACMS, has relevant financial relationships with Lazarus AI, Science 37 (Stock/Shareholder); Regeneron, Sanofi (Speaker/Speaker’s Bureau); Almirall, Jounce Therapeutics, PhD Biosciences, Regeneron (Consultant); Almirall, Regeneron, Sanofi (Advisor).

David M. Miller, MD, PhD, FAAD, has relevant financial relationships with Checkpoint Therapeutics (Stock/Shareholder); Castle Biosciences, Checkpoint Therapeutics, EMD Serono, Merck KGaA, Merck Sharpe & Dome, Pfizer, Regeneron, Sanofi Genzyme (Advisory/Consultant); Kartos Therapeutics, NeoImmuneTech, Regeneron (Grants/Research Support).

Krista M. Rubin, MS, RN, FNP-BC, has relevant financial relationships with BMS, Eisai, Merck (Advisor).

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Joint Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Interprofessional Continuing Education
This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

• Read the learning objectives and faculty disclosures
• Participate in the activity
• Complete the activity evaluation and attest to credit

There is no fee for this educational activity.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Activity Details

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for dermatology and medical oncology clinicians (MD/DO/NP/PA) involved in the care of patients with nonmelanoma skin cancers (NMSC).

Learning Objectives

Upon completion of this activity, participants should be better able to:

• Select appropriate immunotherapy for patients with advanced nonmelanoma skin cancer (NMSC) based on current safety and efficacy data
• Integrate the unique roles and responsibilities of the interprofessional care team when managing patients with advanced NMSC

Activity Description

This activity features an interprofessional, multidisciplinary panel of experts offering privileged insights on evidence-based immunotherapy selection and collaborative care in advanced cutaneous squamous cell carcinoma (CSCC) and basal cell carcinoma (BCC).

Chair

Vishal Anil Patel, MD, FAAD, FACMS
Director, Cutaneous Oncology, GW Cancer Center
Director, Dermatologic Surgery, GW Department of Dermatology
Assistant Professor, Dermatology & Hematology/Oncology
Washington, DC

Faculty

David M. Miller, MD, PhD, FAAD
Medical Oncologist, Dermatologist
Massachusetts General Hospital
Director, Center for Merkel Cell Carcinoma
Co-Director, NMSC Multi-Disciplinary Clinic
Department of Medicine, Division of Hematology/Oncology
Department of Dermatology
Massachusetts General Cancer Center
Boston, MA

Krista M. Rubin, MS, RN, FNP-BC
Nurse Practitioner, Center for Melanoma
Massachusetts General Hospital
Boston, MA

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.

Faculty

Vishal Anil Patel, MD, FAAD, FACMS, has relevant financial relationships with Lazarus AI, Science 37 (Stock/Shareholder); Regeneron, Sanofi (Speaker/Speaker’s Bureau); Almirall, Jounce Therapeutics, PhD Biosciences, Regeneron (Consultant); Almirall, Regeneron, Sanofi (Advisor).

David M. Miller, MD, PhD, FAAD, has relevant financial relationships with Checkpoint Therapeutics (Stock/Shareholder); Castle Biosciences, Checkpoint Therapeutics, EMD Serono, Merck KGaA, Merck Sharpe & Dome, Pfizer, Regeneron, Sanofi Genzyme (Advisory/Consultant); Kartos Therapeutics, NeoImmuneTech, Regeneron (Grants/Research Support).

Krista M. Rubin, MS, RN, FNP-BC, has relevant financial relationships with BMS, Eisai, Merck (Advisor).

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Joint Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Interprofessional Continuing Education
This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

• Read the learning objectives and faculty disclosures
• Participate in the activity
• Complete the activity evaluation and attest to credit

There is no fee for this educational activity.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Activity Details

Provided By

RMEI Medical Education, LLC

Target Audience

This educational activity is designed to meet the needs of medical oncology physicians, dermatology physicians, and other clinicians involved in the management of basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (CSCC).

Learning Objectives

Upon completion of this activity, participants should be better able to:

• Integrate immunotherapy in the management of patients with advanced basal cell carcinoma (BCC) based on the latest clinical trial data
• Select appropriate immunotherapy for advanced cutaneous squamous cell carcinoma (CSCC) based on current safety and efficacy data

Activity Description

As immunotherapy gains momentum in the treatment of nonmelanoma skin cancer, clinicians may be challenged by questions regarding optimal timing and integration in patient care. In this program, experts provide privileged insights into real-world cases submitted by dermatologists and oncologists.

Co-Chairs

Karl D. Lewis, MD
Professor, Medicine
Division of Medical Oncology
Cutaneous Oncology Program
University of Colorado
Aurora, CO

Ahmad Tarhini, MD, PhD
Senior Member, Cutaneous Oncology and Immunology
Director, Cutaneous Clinical and Translational Research
H. Lee Moffitt Cancer Center and Research Institute
Professor, Oncologic Sciences
University of South Florida Morsani College of Medicine
Tampa, FL

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.

Faculty

Karl D. Lewis, MD, has relevant financial relationships with Merck, Pfizer, Regeneron, Roche, Sanofi (Consultant); BMS, Genentech, Incyte, Iovance, Kartos, Merck, Nektar Therapeutics, OncoSec, Pfizer/Array, Regeneron, Replimune, Seattle Genetics, Senhwa, Ultimovacs (Grant/Research Support).

Ahmad Tarhini, MD, PhD, has relevant financial relationships with Bristol Myers Squibb, Clinigen, Eisai, Genentech-Roche, Merck, Novartis, Partner Therapeutics, Regeneron, Sanofi Genzyme (Consultant); Bristol Myers Squibb, Clinigen, Genentech-Roche, Navigate, Nektar Therapeutics, OncoSec, Regeneron, Sanofi Genzyme (Researcher).

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Joint Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hour(s).

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 100% on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

• Read the learning objectives and faculty disclosures
• Participate in the activity
• Complete the activity evaluation and attest to credit

Physicians claiming ABIM MOC points must provide ABIM ID and month/date of birth and score 100% on the post-test.

For Physicians: MOC points will be submitted to ABIM profiles within 4 weeks of completion.

There is no fee for this educational activity.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Activity Details

Provided By

RMEI Medical Education, LLC

Target Audience

This educational activity is designed to meet the needs of medical oncology physicians, dermatology physicians, and other clinicians involved in the management of basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (CSCC).

Learning Objectives

Upon completion of this activity, participants should be better able to:

• Integrate immunotherapy in the management of patients with advanced basal cell carcinoma (BCC) based on the latest clinical trial data
• Select appropriate immunotherapy for advanced cutaneous squamous cell carcinoma (CSCC) based on current safety and efficacy data

Activity Description

As immunotherapy gains momentum in the treatment of nonmelanoma skin cancer, clinicians may be challenged by questions regarding optimal timing and integration in patient care. In this program, experts provide privileged insights into real-world cases submitted by dermatologists and oncologists.

Co-Chairs

Karl D. Lewis, MD
Professor, Medicine
Division of Medical Oncology
Cutaneous Oncology Program
University of Colorado
Aurora, CO

Ahmad Tarhini, MD, PhD
Senior Member, Cutaneous Oncology and Immunology
Director, Cutaneous Clinical and Translational Research
H. Lee Moffitt Cancer Center and Research Institute
Professor, Oncologic Sciences
University of South Florida Morsani College of Medicine
Tampa, FL

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.

Faculty

Karl D. Lewis, MD, has relevant financial relationships with Merck, Pfizer, Regeneron, Roche, Sanofi (Consultant); BMS, Genentech, Incyte, Iovance, Kartos, Merck, Nektar Therapeutics, OncoSec, Pfizer/Array, Regeneron, Replimune, Seattle Genetics, Senhwa, Ultimovacs (Grant/Research Support).

Ahmad Tarhini, MD, PhD, has relevant financial relationships with Bristol Myers Squibb, Clinigen, Eisai, Genentech-Roche, Merck, Novartis, Partner Therapeutics, Regeneron, Sanofi Genzyme (Consultant); Bristol Myers Squibb, Clinigen, Genentech-Roche, Navigate, Nektar Therapeutics, OncoSec, Regeneron, Sanofi Genzyme (Researcher).

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Joint Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hour(s).

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 100% on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

• Read the learning objectives and faculty disclosures
• Participate in the activity
• Complete the activity evaluation and attest to credit

Physicians claiming ABIM MOC points must provide ABIM ID and month/date of birth and score 100% on the post-test.

For Physicians: MOC points will be submitted to ABIM profiles within 4 weeks of completion.

There is no fee for this educational activity.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.